Cohance's niche tech sales rise, pharma CDMO grows, specialty chemicals and API+ see strong gains.

• Niche modalities like ADCs, oligonucleotides boost revenue, targeting mid‑20s percent FY26 for future growth targets.
• Pharma CDMO revenue up over 30% excluding de‑stocking, driven by strong commercial execution and innovation.
• Specialty chemicals rise 28% on AgChem recovery; API+ climbs 19% with new launches driving profits.